Condition
Oligometastatic Prostate Cancer (OMPC) clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Oligometastatic Prostate Cancer (OMPC) clinical trials that are recruiting, at sites in 27 countries (most in United States (3), France (2), Argentina (1)). By phase: Phase 1 (2), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 27Countries
Newest Oligometastatic Prostate Cancer (OMPC) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| JUR-003 in adults with advanced prostate cancer | Phase 1 | Grand Rapids, Michigan and 3 other locations | Recruiting | Sep 17, 2026 |
| DNA vaccine plus nivolumab and targeted radiation for recurrent oligometastatic prostate cancer | Phase 1 | Madison, Wisconsin | Recruiting | Jul 29, 2025 |
| SRT for bone and lymph node metastases in advanced prostate cancer | — | Saint-Herblain | Recruiting | May 18, 2025 |
| Comparing Lutetium (177Lu) vipivotide tetraxetan to observation in oligometastatic prostate cancer | Phase 3 | Fayetteville, Arkansas and 143 other locations | Recruiting | Jul 11, 2023 |
All recruiting trials (4)
-
JUR-003 in adults with advanced prostate cancer
This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.
-
DNA vaccine plus nivolumab and targeted radiation for recurrent oligometastatic prostate cancer
This study will try a DNA vaccine called pTVG-HP together with the checkpoint blocker nivolumab and targeted radiation to see if they can eliminate metastatic tumors in men with non-castrate, recurrent oligometastatic prostate cancer.
-
SRT for bone and lymph node metastases in advanced prostate cancer
This trial tests whether treating multiple metastatic lesions with stereotactic radiotherapy can prolong pain control and prevent complications in men with advanced, treatment‑refractory prostate cancer.
-
Comparing Lutetium (177Lu) vipivotide tetraxetan to observation in oligometastatic prostate cancer
This study is testing a new treatment called lutetium (177Lu) vipivotide tetraxetan to see if it can help people with oligometastatic prostate cancer live better and longer after their previous therapy, compared to just watching their condition.
Related topics
Quick answers
How many Oligometastatic Prostate Cancer (OMPC) clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 27 countries. The most sites are in United States (3 trials), France (2 trials), Argentina (1 trial), Australia (1 trial), Austria (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.